Development and Evaluation of Transdermal Patches of Piperine Hydrochloride

The objective of the present study was to develop transdermal matrix patch of Piperine HCl and assess its feasibility for transdermal application. Low dose maintenance therapy of Piperine HCl has the capability to reduce potential side effects and improved patient compliance which are more common with conventional drug delivery. The results of Piperine HCl transdermal matrix patch showed that the most promising formulation was HE1 (formulation containing Drug: HPMC:EC:Span:PG; (1:(2:8)). Thus optimized transdermal matrix patch of Piperine HCl using polymers such as HPMC and EC with Span & PG as permeation enhancers demonstrated their ability to give sustained release, because of excellent release and permeation of drug and its influence on its pharmacological responses.  The developed formulation of Piperine HCl is expected to improve the patient compliance, form better dosage regimen and provide maintenance therapy to patients suffering from inflammation and allergy.  These promising results showed the feasibility of delivering Piperine HCl through transdermal matrix patch. The developed transdermal patches of Piperine HCl may prove to be a better alternative to conventional dosage forms in allergy as revealed by the results.